ReviewAnti-cancer agents in medicinal chemistry2026
Drug Release, Entrapment Efficacy, and Drug Loading Capacity of Taxanes Loaded Solid Lipid Nanoparticles (SLNs).
Review in Anti-cancer agents in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSolid lipid nanoparticles (SLNs) are submicron carriers with great promise in revolutionizing cancer therapy. They offer a potential solution to the side effects of conventional anticancer drugs, such as systemic toxicity and non-specific distribution. Taxanes, a widely used class of anticancer agents, have been increasingly incorporated into nano-lipid formulations (NLFs) to enhance their therapeutic index.
objectiveDesigning optimal SLN formulations with enhanced drug loading capacity (DLC%), entrapment efficiency (EE%), and controlled drug release profiles is a significant challenge in pharmaceutical nanotechnology. This review, the first of its kind, systematically explores the key factors influencing EE%, DLC%, and the release behavior of Taxane-loaded SLNs. It provides a comprehensive and updated perspective, equipping you with the latest knowledge in this field.
methodsThis narrative review adopts a comprehensive approach to examine the formulation variables that affect EE%, including lipid type, drug properties, surfactants, co-surfactants, emulsifiers, and conjugates. It also outlines the critical parameters that influence drug release, such as particle size, co-loaded drugs, types of lipids and emulsifiers, surface modifiers, release media, and environmental conditions, including pH. The review process involved thoroughly analyzing existing literature and studies in pharmaceutical nanotechnology.
resultsNumerous studies demonstrate that EE% is significantly affected by the physicochemical properties of both the drug and lipid matrix and the choice and concentration of surfactants (e.g., Poloxamer, Tween-80, Solutol HS-15, lecithin). Certain modifications, such as conjugation with Hyaluronic acid, Chitosan derivatives, and PEGylation, tend to lower EE% but improve targeted release. Incorporation of compounds like α-lipoic acid, Ketoconazole, or co-loaded PTX and DTX results in a slower drug release profile. Conversely, siRNA incorporation often accelerates drug release. The release rate is also modulated by environmental pH and the nature of the lipid carriers. Ideal SLN formulations demonstrate high EE% and DLC% along with sustained and controlled release of Taxanes.
conclusionMultiple formulation and environmental factors influence EE%, DLC%, and the drug release behavior of Taxane-loaded SLNs. Understanding these variables is not just important, but it is the key to rationalizing effective and stable nano-lipid formulations in cancer therapy. It is a fascinating and crucial area of study that demands our attention.
Indexed as
Identifiers
41508960What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.